Lucid Capital analyst Dev Prasad initiated coverage of Cue Biopharma (CUE) with a Buy rating and $4 price target The company’s lead asset CUE-401 is a novel bispecific for autoimmune disease, the analyst tells investors in a research note. The firm believes preclinical data show “strong mechanistic validation and broad efficacy” across autoimmune models.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CUE:
- Cue Biopharma’s Q2 2025: Strategic Advances and Financial Highlights
- Cue Biopharma announces initiation of investigator sponsored trial of CUE-102
- Cue Biopharma provides clinical update on CUE-101, saw ORR of 50%
- Cue Biopharma Amends License Agreement with MIL 40G
- Cue Biopharma announces presentation of new CUE-101 data